Comparison of therapeutic effects of acarbose and metformin under different β-cell function status in Chinese patients with type 2 diabetes

Endocrine journal

Jing Fu¹  Jia Liu² 

[1] Department of Endocrinology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, P. R. of China;Department of Endocrinology, China-Japan Friendship Hospital, Beijing 100029, P. R. of China

关键词: Acarbose;    Metformin;    β-cell function;    Chinese;    Type 2 diabetes;   

DOI  :  10.1507/endocrj.EJ18-0466

学科分类：内分泌与代谢学

来源: Japan Endocrine Society

【 摘 要 】

MARCH study suggested that acarbose had similar therapeutic effect on glycated hemoglobin reduction compared to metformin in newly diagnosed type 2 diabetes patients as initial therapy in China. We aimed to investigate whether the efficacy of acarbose was still similar to metformin under different β-cell function status. According to the homeostasis model assessment (HOMA)-β level, 670 patients were divided into better β-cell function group, medium β-cell function group and poor β-cell function group. Patients received acarbose 300 mg/d or metformin 1,500 mg/d for 48 weeks. We found both acarbose and metformin could decrease glycated hemoglobin to similar levels after 48 weeks treatment in all groups. In medium β-cell function group, the decrease of fasting blood glucose after metformin treatment was more significant compared to acarbose (p = 0.040); however, the decrease of post-challenge blood glucose after acarbose treatment was more significant compared to metformin (p = 0.020). Moreover, in poor β-cell function group, the decrease of body weight and body mass index after acarbose treatment were significant compared to metformin (p = 0.004 and p = 0.031, respectively). Therefore, acarbose contributed a similar therapeutic effect to plasma glucose control compared to metformin treatment, even under different β-cell function status.

【 授权许可】

Unknown